PDCD4 inhibits the malignant phenotype of ovarian cancer cells

Zeng-Tao Wei1, Xia Zhang, Xiao-Yan Wang

  • 1Institute of Immunology, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Jinan, China.

Cancer Science
|June 5, 2009
PubMed

Insights

Programmed cell death 4 (PDCD4) suppresses ovarian cancer progression by inhibiting cell proliferation and inducing apoptosis. Upregulating PDCD4 reduces tumor growth, suggesting it as a potential therapeutic target for ovarian carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Programmed cell death 4 (PDCD4) is a tumor suppressor involved in inhibiting activator protein (AP)-1 activation and protein translation.
  • Reduced PDCD4 expression is linked to ovarian carcinoma progression, but direct evidence of its tumor-suppressive role in human cancer cells is limited.

Purpose of the Study:

  • To investigate the direct impact of PDCD4 on the malignant phenotype of human ovarian cancer cells.
  • To evaluate PDCD4's potential as a therapeutic target for ovarian cancer.

Main Methods:

  • Assessing PDCD4 expression in ovarian cancer cell lines (SKOV3, 3AO, CAOV3).
  • Analyzing the effects of PDCD4 modulation on cell proliferation, cell cycle progression, and apoptosis.
  • Evaluating the impact of PDCD4 on colony-forming capacity in vitro and tumorigenic capacity in vivo (mice).

Main Results:

  • PDCD4 expression significantly inhibited proliferation and cell cycle progression in ovarian cancer cell lines.
  • Increased PDCD4 expression induced apoptosis in these cells.
  • Upregulation of PDCD4 reduced colony formation in vitro and tumor growth in mice.

Conclusions:

  • PDCD4 effectively suppresses the malignant phenotype of ovarian cancer cells.
  • PDCD4 represents a promising novel therapeutic target for ovarian cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...